Search: L773:0016 5085 OR L773:1528 0012
> Högskolan Dalarna >
Association between...
Association between proton pump inhibitor use and risk of progression of chronic kidney disease
-
Klatte, Derk C F (author)
-
- Gasparini, Alessandro (author)
- Karolinska Institutet
-
- Xu, Hong (author)
- Karolinska Institutet
-
show more...
-
de Deco, Pietro (author)
-
- Trevisan, Marco (author)
- Karolinska Institutet
-
- Johansson, Anna L V (author)
- Karolinska Institutet
-
- Wettermark, Björn (author)
- Karolinska Institutet
-
- Ärnlöv, Johan, 1970- (author)
- Karolinska Institutet,Högskolan Dalarna,Medicinsk vetenskap,Uppsala universitet
-
Janmaat, Cynthia J (author)
-
- Carrero, Juan J (author)
- Karolinska Institutet
-
- Lindholm, B (author)
- Karolinska Institutet
-
Dekker, FW (author)
-
Coresh, J (author)
-
Grams, ME (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2017
- 2017
- English.
-
In: Gastroenterology. - : Elsevier BV. - 0016-5085 .- 1528-0012. ; 153:3, s. 702-710
- Related links:
-
http://www.gastrojou...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with acute kidney injury (AKI) and recent studies suggest that they may be associated with the risk of chronic kidney disease (CKD).METHODS: We performed a retrospective analysis using the Stockholm creatinine measurements database, which contains information on diagnoses, dispensation claims, and laboratory test results for all citizens in the Stockholm region from 2007 through 2010. We identified new users of PPIs (n= 105305) and new users of H2 blockers (H2B; n= 9578); data on renal outcomes were collected for a median 2.7 years. The primary outcome was progression CKD, defined as doubling of creatinine or decrease in estimated glomerular filtration rate of 30% or more. Secondary outcomes were end-stage renal disease and acute kidney injury (AKI). Complete collection of repeated PPI and H2B dispensations at pharmacies in Sweden allowed modeling the time-dependent risk associated to cumulative PPI exposure.RESULTS: Users of PPIs, compared to users of H2Bs, had an increased risk for doubled levels of creatinine (1985 events; adjusted hazard ratio [HR], 1.26; 95% CI, 1.05-1.51) and decrease in estimated glomerular filtration rate of 30% or more (11045 events; 1.26; 95% CI, 1.16-1.36). PPI use also associated with development of end-stage renal disease (HR, 2.40; 0.76-7.58) and AKI (HR, 1.30; 95% CI, 1.00-1.69). There was a graded association between cumulative exposure to PPIs and risk of CKD progression. This was not the case for cumulative H2B use.CONCLUSIONS: Initiation of PPI therapy and cumulative PPI exposure associate with increased risk of CKD progression in a large, North European healthcare system. Although consistent, the association was modest in magnitude, and cannot exclude residual confounding.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- SCREAM
- eGFR
- omeprazole
- pharmacoepidemiology
- Hälsa och välfärd
- Health and Welfare
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Klatte, Derk C F
-
Gasparini, Aless ...
-
Xu, Hong
-
de Deco, Pietro
-
Trevisan, Marco
-
Johansson, Anna ...
-
show more...
-
Wettermark, Björ ...
-
Ärnlöv, Johan, 1 ...
-
Janmaat, Cynthia ...
-
Carrero, Juan J
-
Lindholm, B
-
Dekker, FW
-
Coresh, J
-
Grams, ME
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
Gastroenterology
- By the university
-
Högskolan Dalarna
-
Karolinska Institutet